Back to News
Market Impact: 0.08
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
Source: GlobeNewswire
Healthcare & Biotech
The Shared Goals: Navigating Alzheimer’s Agitation survey found that agitation associated with Alzheimer’s disease is frequently not recognized until it has significantly disrupted daily life. The findings underscore a potential gap in earlier identification and management of behavioral symptoms, but do not provide financial, clinical-trial, or company-specific data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why is Labcorp stock sliding today?
- Why is Quest Diagnostics stock sliding today?
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard